Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
54.7M
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
63.4M
-
Shares change
-
+5.32M
-
Total reported value, excl. options
-
$422M
-
Value change
-
+$30.3M
-
Put/Call ratio
-
48.79
-
Number of buys
-
68
-
Number of sells
-
-55
-
Price
-
$6.65
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q1 2025
155 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2025.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.4M shares
.
Largest 10 shareholders include Skorpios Trust (6.91M shares), BlackRock, Inc. (5.86M shares), Lynx1 Capital Management LP (5.29M shares), RTW INVESTMENTS, LP (5.12M shares), BAKER BROS. ADVISORS LP (4.63M shares), Redmile Group, LLC (4.49M shares), MORGAN STANLEY (3.59M shares), TORONTO DOMINION BANK (3.17M shares), VANGUARD GROUP INC (2.78M shares), and FMR LLC (2.54M shares).
This table shows the top 124 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.